Adcock Ingram Integrated Report 2018

25 ADCOCK INGRAM  Integrated Report 2018 ThePainportfolio isthemarket leader in prescription pain management, and includes a comprehensive portfolio of brands that offer healthcare professionals and patients effective pain solutions covering: u u mild to severe acute pain; u u chronic pain related to cancer or auto-immune diseases; and u u a variety of dosage forms including oral, topical, parenteral and transdermal preparations. The pain portfolio includes leading, well-known brands such as Myprodol, Synaleve, Mypaid Forte and Myprocam. In the coming year this division will expand its chronic pain offering by introducing two innovative, long-acting transdermal patches for the treatment of neuropathic pain. Women’s Health recognises and celebrates the uniqueness of women. The portfolio includes treatments related to menopause, vaginal dryness, urinary tract infections (UTIs) and osteoporosis. Women’s Healthcare is proud to provide quality treatment options to meet the needs of South African women through specific stages of their journey through life. We are passionate about empowering women through information about healthcare and personal matters, helping women make informed decisions about their health and the treatment options available. The hormone therapy portfolio which includes Adcock Ingram’s as well as partner brands is the leader in its class as measured in IQVIA. The CNS portfolio has established itself as a multinational partner of choice for CNS brands in the private and public sector, promoting and distributing key brands such as Cipramil, Cipralex, Fluanxol and Rivotril. This portfolio also includes well known Adcock Ingram brands such as Stresam and offers treatments covering a range of conditions, such as depression, anxiety, epilepsy, Alzheimer’s and schizophrenia. Dermatology covers a wide spectrum of dermatological conditions, including acne, eczema, emollients for dry skin, and brands for skin infections and psoriasis. Whilst most of these conditions are not life threatening, they significantly affect the patient’s quality of life.The portfolio is comprised of brands frommainly two partners, namely Leo Pharma and Roche Holding AG.The 2018 financial year saw the full integration of the former Astellas products Protopic, SBR, Locoid and Zineryt into the Adcock Ingram stable, after the global acquisition of these brands by Leo Pharma.The expanded Dermatology portfolio now offers healthcare professionals a broader armamentarium in treating dermatological conditions, and has successfully positioned Adcock Ingram as the 2nd largest prescription dermatology franchise in the country, including well-known brands such as Fucidin, Roaccutane, Dovobet, Protopic and SBR Lipocream. The Generics portfolio contributes approximately one-third towards the division’s revenue and consists of products which span the major therapeutic areas such as CNS, cardiovascular and pain. This diverse portfolio consists of brands which treat both acute and chronic diseases and are predominantly found within the prescription medication space. Adcock Ingram’s anti-retroviral (ARV) portfolio consists of a range of high quality, cost effective, first and second line treatment options for adults and children living with the Human Immunodeficiency Virus (HIV).Trivenz, which is Adcock Ingram’s once daily, single tablet regimen for the treatment of HIV, is currently the Company’s leading prescription brand, providing treatment to approximately 70,000 people in the private sector.The brand is currently the fastest growing prescription brand in theTop 10 pharmaceutical brands in SA, and is currently the second most dispensed anti-retroviral brand in the private sector prescription market. PERFORMANCE BUSINESS FOCUS u u Remain the multinational partner of choice. u u Drive growth and market access within the generics portfolio. u u Enter into high value and specialty markets with biosimilars and novel pain products. u u Leading supplier of locally manufactured ARVs to the private and public sectors. u u Improve factory capacity utilisation. u u Introduce products and partnerships in new or additional therapeutic areas. Pain Women’s Health CNS Dermatology Generics Anti-retroviral (ARV) MARKET TRENDS u u Shift in disease burden from infectious diseases (such as HIV and TB) to chronic diseases (South African Generics Market Outlook 2017-2022). u u The ARV market faces significant pricing pressure from generic competition and funders. u u The growth of house brand strategies, driven by corporate pharmacy groups, limits market penetration of generics. u u Increased interest in biosimilars. u u Pricing pressures, driven by funders, continue to shape the private market, by driving a switch to generics. ACHIEVEMENTS IN 2018 u u The acquisition of Genop in the second half of the financial year. u u The division continued to build on the strategy of being the multinational partner of choice with the on-boarding of Aclasta from Novartis in 2018. u u The acquisition of a first to market Arcoxia (Etoricoxib) generic from Specpharm. u u Down-scheduling of Genpayne and Fucidin to Schedule 2, now available over the counter without a prescription. u u Trivenz, for the treatment of HIV, reached R200 million in sales and is cited as the fastest growing brand in the Top 10 pharma brands (SAHCI, May 2018). u u Completion of phase two of the upgrade of the liquids, creams and ointments facility in Wadeville. OVERVIEW The Prescription division is focused on building and offering a broad range of quality and affordable medicines in specific therapeutic areas for patients consulting healthcare professionals, generally where prescriptions are required. During the year the business acquired Genop (refer page 14), a specialised instrument, surgical and pharmaceutical products company focused on the ophthalmic, optometry, skincare, aesthetic and plastic surgery segments in Southern Africa, and which also owns and markets the well-known Epi-Max range. The division manufactures products in South Africa and India, as well as sourcing products from a range of partner companies, primarily based in Europe. The portfolios of products are grouped according to therapeutic areas in order to facilitate promotion to relevant medical specialists: